Finland-based firm Injeq has announced the expansion of clinical trials of its IQ-Needle to University Children’s Hospitals in Denmark, Norway and Sweden, following a successful crowdfunding in Europe.

The tissue-identifying Injeq IQ-Needle features a unique electrode and the firm’s BZ-301 analyser for advanced real-time information.

The electrode enables bioimpedance measurement of the tissue that is in contact with the needle’s tip, while the low energy measurement signal allows the analyser to identify changes due to tissue contact, and calculate the impedance in different frequency points.

Designed for clinical applications such as regional anaesthesia, lumbar punctures, biopsy, and intra-tumoural drug delivery, the device is expected to improve diagnosis, minimise complications, and facilitate new treatments for patients.

Being tested for use in paediatric acute lymphatic leukaemia (ALL) patients who receive traumatic lumbar punctures, the needle is expected to improve the success rate, as well as minimise trauma and bleeding in newborns and children due to the punctures.

"The device is expected to improve diagnosis, minimise complications, and facilitate new treatments for patients."

The characteristic of the needle to alert the physician upon contact with the target spinal fluid allows prevention of complications associated with excessive needle penetration.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Injeq Clinical Development and Sales vice-president Dr Rami Lehtinen said: “International studies are an important step in demonstrating the benefits of Injeq IQ-Needle. Preparations and planning for new studies have now been started.”

The Karolinska University Hospital at Stockholm, Sweden, is also set to initiate a clinical trial of the needle in premature infants who are prescribed to receive a lumbar puncture.

The results from previous clinical trials conducted in Finland are reported to be encouraging.